At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 5 enrolled
Drug / intervention
Tisotumab Vedotindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Open-label Trial Investigating the Efficacy and Safety of Continued Treatment With Tisotumab Vedotin in Patients With Solid Tumors Known to Express Tissue Factor.
In Brief
A Phase 2 clinical trial evaluating Tisotumab Vedotin for Ovary Cancer and 7 related conditions. Completed, enrolled 5 participants across 4 sites in 2 countries.
Detailed Summary
The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer, Esophagus Cancer, Lung Cancer, Nonsmall Cell, Squamous Cell Carcinoma of the Head and Neck
CountriesUnited Kingdom, United States
CollaboratorsGenmab
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartAug 2017
Primary CompletionJan 2019
TodayJul 2026
First PostedAug 10, 2017
Enrollment StartAug 23, 2017
Primary CompletionJan 10, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 8.9 years ago
Interventions
Tisotumab Vedotindrug
All patients in the trial will be administered tisotumab vedotin (HuMax-TF-ADC).